[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"uremia-chronic\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:uremia-chronic":31},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,46,82,119,151,172,205],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":4},"100622168","phase-4-anrikefon-vs-nalfurafine-for-sleep-quality-in-hemodialysis-patients-with-ckd-ap-100622168",false,"NCT07380113","Anrikefon vs Nalfurafine for Sleep Quality in Hemodialysis Patients With CKD-aP","An Exploratory Study Comparing Anrikefon With Nalfurafine in Improving Sleep Quality Among CKD-aP Patients Undergoing Hemodialysis: An Open-Label Randomized Controlled Clinical Trial","Anrikefon","Inclusion Criteria:\n\n1. Be able to understand the procedures and methods of this trial, be willing to strictly follow the clinical research protocol to complete this trial, and voluntarily sign the informed consent form.\n2. Male or female individuals aged 18 or above and 75 or above.\n3. Patients with end-stage renal disease received regular hemodialysis three times a week before the screening period (whether they met the requirements for regular dialysis was determined based on the opinions of the researchers).\n4. Meet the diagnostic criteria for chronic kidney disease-associated pruritus (CKD-aP).\n\n   1. Patients with chronic kidney disease (CKD) presenting with pruritus, with other identifiable causes of pruritus excluded.\n   2. Pruritus occurring on at least 3 days within a 2-week period, with multiple episodes per day, each lasting for several minutes, and having an impact on the patient's daily life.\n   3. Recurrent pruritus persisting for at least 6 weeks.A diagnosis requires that all three criteria above be met simultaneously.\n5. The subjects were evaluated using the Worst Itch Numerical Rating Scale (WI-NRS) for the most severe pruritus intensity and met the baseline pruritus intensity of ≥ 4 points.\n6. The subjects have completed the Pittsburgh Sleep Quality Index (PSQI) assessment during the screening period and met the baseline PSQI score \\> 7 points.\n\nExclusion Criteria:\n\n1. Participants with other serious systemic diseases that may affect their ability to participate in the study, as assessed by the investigator, including but not limited to:\n\n   1. Severe cardiovascular diseases, such as unstable angina, myocardial infarction, severe arrhythmias, World Health Organization (WHO) heart function classification III-IV during screening, poorly controlled hypertension or hypotension despite active treatment, and recurrent asthma.\n   2. A history of cerebrovascular accident (CVA) within the last 6 months.\n   3. Malignant tumors, excluding those that are curable, such as cervical carcinoma in situ, basal cell carcinoma or squamous cell carcinoma of the skin, or any other cancer that has been cured (with no evidence of disease recurrence for 5 years).\n2. It is expected to undergo kidney transplantation and\u002For parathyroidectomy during the study period.\n3. The subjects are currently undergoing ultraviolet B treatment or are expected to receive such treatment during the study period.\n4. Have participated in any clinical trials of other drugs or medical devices within one month prior to screening (treatment with drugs or medical devices that have received clinical trials).\n5. Patients who have used the following drugs within 7 days before screening:\n\n   1. those who have used opioids.\n   2. those who must use opioids other than the investigational drug during the study period.\n   3. those who has used gabapentin, pregabalin and calcineurin inhibitors;\n   4. those who use drugs that can affect the efficacy judgment of anti-itching, including but not limited to antipsychotic drugs, sedative-hypnotic drugs, selective serotonin reuptake inhibitors (SSRIs), anti-anxiety drugs, or tricyclic antidepressants.\n6. After screening and enrollment, new antihistamines (such as antihistamines and corticosteroids, etc. (oral, intravenous or topical)) were prescribed, or the types, dosages or frequencies of these drugs were changed.\n7. Patients who have used any hypnotic or sedative medications (including benzodiazepine hypnotics, non-benzodiazepine hypnotics, melatonin receptor agonists, etc.) within 1 month prior to the screening period and baseline assessment.\n8. There is a history of allergy to opioid drugs, or it is known that there is a history of allergy to investigatory drugs or components of remedial drugs or other drugs or excipients with similar chemical structures.\n9. Severe hematological and liver function abnormalities during screening, meeting any one of the following clinical laboratory test results:\n\n   1. Hematology: Hemoglobin \\\u003C 80g\u002FL.\n   2. Liver function:\n\n      * Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \\> 2.5× upper limit of normal (ULN).\n      * Total bilirubin (TBIL) \\> 2×ULN.\n10. Subjects who had any active infections during screening and whom the researchers considered unsuitable for inclusion (including but not limited to acute hepatitis, skin infections, etc.).\n11. As determined by the researchers, any other physical or mental illness or condition that may increase the risk of the trial, affect the subjects' compliance with the protocol, or affect the subjects' completion of the trial.","ALL","18 Years","75 Years",{"count":21,"type":22},50,"ESTIMATED","INTERVENTIONAL",[25],"PHASE4","The goal of this clinical trial is to compare a new intravenous drug, Anruikefen, with a traditional oral medication, nalfurafine orally disintegrating tablets, in improving sleep quality in patients with chronic kidney disease-associated pruritus. Sleep quality will be primarily assessed using the Pittsburgh Sleep Quality Index (PSQI). The study will also evaluate the safety of Anruikefen.\n\nThe main questions it aims to answer are:\n\n* Does Anruikefen injection improve sleep quality better than oral nalfurafine?\n* Does Anruikefen injection improve patients' quality of life more than oral nalfurafine? Researchers will compare Anruikefen with nalfurafine (an active control drug) to evaluate differences in their effects on sleep quality in patients with chronic kidney disease-associated pruritus.\n\nParticipants will:\n\n* Receive either Anruikefen injection (0.3 μg\u002Fkg, three times per week) or nalfurafine hydrochloride orally disintegrating tablets (2.5 μg once daily).\n* Continue treatment for 4 weeks, followed by a 1-week safety follow-up.\n* Complete the Pittsburgh Sleep Quality Index and other quality-of-life questionnaires after one month.",[28,29,30,31,32,33],"Pruritus Chronic","Kidney Diseases, Chronic","Renal Insufficiency, Chronic","Uremia; Chronic","Pruritus Due to Systemic Disorder (Disorder)","Pruritus Due to Hemodialysis","NOT_YET_RECRUITING","2026-06-14",{"date":37,"type":38},"2026-06-16","ACTUAL",{"date":40,"type":22},"2026-07-01",{"date":42,"type":22},"2027-12-31",{"name":44,"class":45},"Zhujiang Hospital","OTHER",{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":54,"targetDuration":56,"studyType":57,"phases":4,"briefSummary":58,"conditions":59,"keywords":61,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":81},"100633078","icharus-italian-cooperative-hemoadsorption-study-for-relief-of-uremic-symptoms-100633078","NCT07522008","ICHARUS: Italian Cooperative HemoAdsorption Study for Relief of Uremic Symptoms","ICHARUS: Italian Cooperative HemoAdsorption Study for Relief of Uremic Symptoms. A Prospective Observational Cohort Study to Assess the Effectiveness and Safety of Hemoadsorption in Chronic Hemodialysis Patients With Refractory Uremic Symptoms: An Italian Real-World Registry.","ICHARUS","Inclusion Criteria:\n\n* Adult patients (≥18 years) with end-stage kidney disease (CKD stage 5D) on maintenance hemodialysis.\n* Stable hemodialysis treatment for at least 3 months prior to enrollment.\n* Presence of at least one moderate-to-severe uremic symptom, as identified by the Dialysis Symptom Index at screening.\n* Planned treatment with hemodialysis combined with hemoadsorption according to local clinical practice.\n* Ability to provide written informed consent.\n\nExclusion Criteria:\n\n* Acute illness, active infection, or hospitalization within 4 weeks prior to enrollment.\n* Planned kidney transplantation within the study follow-up period.\n* Life expectancy less than 6 months due to non-renal comorbid conditions.\n* Inability to complete patient-reported outcome questionnaires.\n* Participation in another interventional clinical study that could interfere with study outcomes.",{"count":55,"type":22},120,"6 Months","OBSERVATIONAL","Background:\n\nMany patients receiving maintenance hemodialysis continue to experience persistent uremic symptoms, such as pruritus, fatigue, sleep disorders, reduced physical performance, and impaired quality of life, despite optimized dialysis prescriptions. Conventional dialysis techniques mainly rely on diffusion and convection and may be insufficient to remove certain uremic toxins, particularly protein-bound and middle-molecule solutes.\n\nPurpose:\n\nThe ICHARUS study (Italian Cooperative HemoAdsorption Study for Relief of Uremic Symptoms) is a prospective, observational, real-world registry designed to evaluate the clinical use of hemodialysis combined with hemoadsorption (HAHD) in patients with persistent uremic symptoms.\n\nStudy design:\n\nICHARUS is a multicenter registry enrolling adult patients on maintenance hemodialysis in whom hemoadsorption is prescribed according to routine clinical practice. Hemoadsorption is added to standard dialysis sessions without modifying the underlying dialysis modality or prescription. The study does not involve randomization or experimental interventions.\n\nOutcomes:\n\nThe registry will collect data on patient-reported symptoms, quality of life, selected laboratory parameters, and safety outcomes at baseline and during follow-up at 1, 3, and 6 months. The aim is to describe symptom evolution, tolerability, and real-world treatment patterns associated with HAHD.\n\nSignificance:\n\nBy collecting standardized real-world data across multiple centers, the ICHARUS registry aims to improve understanding of the potential role of hemoadsorption in chronic hemodialysis, support harmonization of clinical practice, and generate hypotheses for future interventional studies.",[60,31],"Chronic Kidney Disease 5D",[62,63,64,65,66,67,68,69,70],"Hemoadsorption","Hemodialysis","HAHD","Protein-bound uremic toxins","Middle molecules","Uremic symptoms","Patient-reported outcomes","Quality of life","Real-world registry","RECRUITING","2026-04-20",{"date":74,"type":38},"2026-04-21",{"date":76,"type":38},"2026-03-15",{"date":78,"type":22},"2027-07",{"name":80,"class":45},"Azienda Ospedaliera Brotzu",1,{"id":83,"slug":84,"hasResults":11,"nctId":85,"briefTitle":86,"officialTitle":87,"acronym":88,"eligibilityCriteria":89,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":90,"targetDuration":4,"studyType":23,"phases":92,"briefSummary":94,"conditions":95,"keywords":100,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":111,"startDateStruct":113,"completionDateStruct":115,"leadSponsor":117,"locationsCount":81},"100619739","expanded-hemodialysis-versus-high-volume-online-hemodiafiltration-for-uremic-toxin-removal-100619739","NCT07348536","Expanded Hemodialysis Versus High-Volume Online Hemodiafiltration for Uremic Toxin Removal","Impact of Expanded Hemodialysis Prescription on Global Uremic Toxin Removal Compared With High-Volume Online Hemodiafiltration: A Randomized Open-Label Crossover Study","REMOV-HDx","Inclusion Criteria:\n\n* Adults aged 18 years or older\n* End stage renal disease Receiving maintenance hemodialysis three times per week on expanded hemodialysis as part of routine care for at least 1 month\n* On dialysis treatment for more than 3 months\n* Minimal or no residual urine output (less than 100 mL per day)\n* Able and willing to provide written informed consent\n\nExclusion Criteria:\n\n* Vascular access unable to support a blood flow of at least 300 mL\u002Fmin",{"count":91,"type":22},15,[93],"NA","People with advanced kidney disease need dialysis to remove waste products from the blood. Some of these waste products, called uremic toxins, are small, while others are medium-sized and more difficult to remove. Poor removal of these toxins may contribute to symptoms and long-term complications in patients on dialysis.\n\nTwo dialysis techniques are commonly used to improve toxin removal beyond standard hemodialysis: expanded hemodialysis (HDx) using medium cut-off membranes, and high-volume online hemodiafiltration (HV-OL-HDF). Although both techniques are effective, the best way to prescribe expanded hemodialysis-particularly the ideal treatment time-has not been clearly defined.\n\nThe purpose of this study is to compare how well different treatment times of expanded hemodialysis remove small and medium-sized uremic toxins, and to compare these results with high-volume online hemodiafiltration. Toxin removal will be evaluated using a combined measurement called the Global Removal Score, which summarizes the removal of several important waste substances.\n\nThis is a single-center, randomized, open-label, crossover study. Adults receiving maintenance hemodialysis will receive three different expanded hemodialysis sessions with different treatment durations (180, 210, and 240 minutes), followed by one session of high-volume online hemodiafiltration. Blood samples will be taken before and after each dialysis session to measure toxin levels.\n\nThe results of this study may help determine whether expanded hemodialysis with shorter or standard treatment times can achieve toxin removal similar to high-volume hemodiafiltration, which could support more personalized and practical dialysis prescriptions.",[96,97,98,31,63,99],"End Stage Renal Disease (ESRD)","Chronic Kidney Disease on Hemodialysis","Renal Dialysis","Hemodiafiltration",[101,102,103,104,105,106,107,108,109],"Expanded hemodialysis","High-volume online hemodiafiltration","Medium cut-off dialysis membranes","Uremic toxin removal","Middle molecule clearance","Chronic kidney failure","Dialysis dose optimization","Dialysis treatment time","Global removal score","2026-03-23",{"date":112,"type":38},"2026-03-24",{"date":114,"type":22},"2026-04",{"date":116,"type":22},"2029-12",{"name":118,"class":45},"Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran",{"id":120,"slug":121,"hasResults":11,"nctId":122,"briefTitle":123,"officialTitle":124,"acronym":125,"eligibilityCriteria":126,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":127,"targetDuration":4,"studyType":23,"phases":129,"briefSummary":130,"conditions":131,"keywords":138,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":142,"lastUpdatePostDateStruct":143,"startDateStruct":145,"completionDateStruct":147,"leadSponsor":149,"locationsCount":81},"100602469","studies-on-adsorption-international-learning-initiative-global-100602469","NCT07123909","Studies on Adsorption International Learning Initiative Global","The Use of Sorption Technologies in Patients Receiving Program Hemodialysis With Inflammatory Syndrome","SAILING","Inclusion Criteria:\n\n1. Adequate dialysis defined by a KT\u002FV index ≥ 1.4\n2. No active inflammatory process or infection\n3. Age ≥ 18 years\n4. Receiving standard hemodialysis regimen three times weekly, at least 4 hours per session\n5. Participants with elevated interleukin-6 (IL-6) and\u002For C-reactive protein (CRP) levels exceeding local laboratory reference values\n\nExclusion Criteria:\n\n1. Current use of steroids or immunosuppressive therapy\n2. History of kidney transplantation\n3. Diagnosis of cancer\n4. Pregnancy",{"count":128,"type":22},60,[93],"Use of sorption technologies in patients undergoing maintenance hemodialysis with inflammatory syndrome and clinical manifestations of uremia",[132,31,133,134,63,135,136,137],"CKD (Chronic Kidney Disease) Stage 5D","Uremic; Toxemia","Inflammation Chronic","Inflammation Biomarkers","Dialysis Related Complication","Anemia Associated With End Stage Renal Disease",[139,140,141],"Program dialysis","Sorption","Complications of program dialysis","2025-12-03",{"date":144,"type":38},"2025-12-10",{"date":146,"type":38},"2025-06-01",{"date":148,"type":22},"2026-06-30",{"name":150,"class":45},"Botkin Hospital",{"id":152,"slug":153,"hasResults":11,"nctId":154,"briefTitle":155,"officialTitle":155,"acronym":4,"eligibilityCriteria":156,"healthyVolunteers":157,"sex":17,"minAge":18,"maxAge":158,"enrollmentInfo":159,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":160,"conditions":161,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":163,"lastUpdatePostDateStruct":164,"startDateStruct":166,"completionDateStruct":168,"leadSponsor":170,"locationsCount":81},"100607529","dynamic-breath-voc-profiling-as-a-non-invasive-tool-to-assess-hemodialysis-adequacy-100607529","NCT07189741","Dynamic Breath VOC Profiling as a Non-invasive Tool to Assess Hemodialysis Adequacy","1: Age:18-85\n\n2: Maintenance hemodialysis (HD) group: diagnosed with chronic kidney disease stage 5 (uremia), receiving regular HD for ≥3 months.\n\n3: Healthy control group: with no history of major acute or chronic diseases.\n\n4: Capable of understanding the research procedures and voluntarily providing written informed consent.\n\n1. Active infection\n2. History or current diagnosis of malignancy\n3. Severe hepatic insufficiency\n4. Unable to comply with breath testing or blood sampling; or refusal or inability to provide informed consent.\n5. Deemed ineligible for participation based on the investigator's judgment.",true,"85 Years",{"count":21,"type":22},"What is this study about? This is an observational study. The goal is to find out whether tiny chemicals in breath, called volatile organic compounds (VOCs), can help show if a hemodialysis session works well enough (\"dialysis adequacy\"). Hemodialysis is a treatment that uses a machine to remove waste and extra fluid from the blood.\n\nMain questions Which breath chemicals change in people receiving hemodialysis when we compare samples collected before dialysis with samples collected after the same dialysis session? Do these changes help indicate whether a dialysis session is adequate (that is, whether it worked as intended)? How do the breath chemicals of people receiving hemodialysis differ from those of healthy adults? During the dialysis session, which blood test results go up or down? Which ones are most different from the usual healthy range? Who can take part Adults aged 18-85 years. Hemodialysis group: people with chronic kidney disease stage 5 who receive maintenance hemodialysis for at least three months.\n\nHealthy comparison group: adults without major acute or chronic illnesses. Final eligibility will follow the approved study protocol and screening. What will happen if you join Hemodialysis group Provide one breath sample before a routine dialysis session and one breath sample after the same session.\n\nHave a small blood draw at those same time points. Your usual medical care will not change because of this study. Healthy comparison group Provide one breath sample and one small blood draw at a single visit. Time and visits For people receiving hemodialysis: both breath and blood samples are collected around one dialysis session (before and after).\n\nFor healthy adults: all procedures are finished in one scheduled visit. The study plans to include about 22 people on hemodialysis and about 23 healthy adults. These numbers may change slightly as enrollment proceeds.\n\nHow your samples are used Breath samples will be analyzed with gas chromatography-mass spectrometry (GC-MS), a laboratory method that separates and identifies very small amounts of chemicals in breath.\n\nBlood samples will be tested for routine biochemistry and immune measures to see which results change during dialysis and which results are different from the healthy range.\n\nThe study does not test a new drug or device and does not change your treatment.\n\nPossible benefits You may not receive a direct benefit. The knowledge from this study may help doctors find simple, non-invasive ways to judge whether dialysis works well, which could improve care for people with kidney failure in the future.\n\nPossible risks or discomforts Breath collection is non-invasive and usually causes no discomfort. Blood draws may cause brief pain, a small bruise, or lightheadedness in some people.\n\nPrivacy and data protection We label samples and data with codes instead of names. Only authorized staff can link the codes to your identity.\n\nStudy results may be published in journals or at meetings, but no information that can identify you will be shared.\n\nWhere and when Location: Shanghai Second People's Hospital (Department of Nephrology, Dialysis Unit).\n\nStudy period: September 1, 2025 to June 30, 2027. Sampling is expected during routine care for people on dialysis and during one visit for healthy adults.\n\nStudy team Principal Investigator: Tao Xiaoyang, Shanghai Second People's Hospital.",[162,31,63],"Uremia","2025-09-22",{"date":165,"type":38},"2025-09-24",{"date":167,"type":22},"2025-09-30",{"date":169,"type":22},"2027-06-30",{"name":171,"class":45},"Second People's Hospital, Shanghai",{"id":173,"slug":174,"hasResults":11,"nctId":175,"briefTitle":176,"officialTitle":177,"acronym":178,"eligibilityCriteria":179,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":180,"enrollmentInfo":181,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":183,"conditions":184,"keywords":187,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":196,"lastUpdatePostDateStruct":197,"startDateStruct":199,"completionDateStruct":201,"leadSponsor":203,"locationsCount":81},"100595500","predictive-value-of-carotid-ultrasonography-for-intradialytic-hypotension-100595500","NCT07033260","Predictive Value of Carotid Ultrasonography for Intradialytic Hypotension","The Predictive Value of Carotid Corrected Flow Time and Peak Flow Velocity Variability for Intradialytic Hypotension: A Prospective Multicenter Observational Study","CUPID","Inclusion Criteria:\n\nAdults aged 18 to 80 years. Diagnosed with end-stage renal disease (ESRD). Undergoing maintenance hemodialysis for more than three months. Willing and able to provide informed consent and comply with study procedures.\n\nExclusion Criteria:\n\nPatients with significant carotid artery stenosis due to heavy atherosclerotic plaque (defined as more than 70% stenosis confirmed by ultrasound or angiography).\n\nHemodynamically unstable patients or those requiring vasopressor support. Patients with significant arrhythmias (e.g., atrial fibrillation, ventricular tachycardia).\n\nDialysis sessions terminated for reasons unrelated to hypotension (e.g., technical issues, patient request).\n\nUse of antihypertensive medications during dialysis sessions. Inability to undergo ultrasound assessment due to factors such as severe obesity or wounds obstructing access.\n\nPatients who withdraw informed consent during the study.","80 Years",{"count":182,"type":22},183,"This multicenter, prospective observational study aims to evaluate the predictive value of carotid corrected flow time (FTc) and peak flow velocity variability (PFVV) for hypotension during maintenance hemodialysis. Conducted at The First Affiliated Hospital of Wannan Medical College, Wuhu City Second People's Hospital, Wuhu Hospital of Chinese Traditional Medicine, Wuhu Jinghu District Hospital, and Wuhu Guangji Hospital, the study will include adult patients (≥18 years) with end-stage renal disease (ESRD) on long-term hemodialysis for at least three months. Patients with acute kidney injury, severe cardiac conditions, or other factors affecting results will be excluded. Ultrasound assessments of FTc and PFVV will be performed once, at 1 hour after dialysis initiation. Blood pressure will be monitored during the procedure. The primary outcome is to determine the sensitivity, specificity, and optimal cutoff points of FTc and PFVV in predicting intradialytic hypotension. The estimated sample size is 183 participants, with analysis performed using ROC curves and multivariate regression. The protocol complies with ethical standards and aims to develop a simple, non-invasive, real-time tool to improve patient safety and individualized management during hemodialysis.",[185,186,31,63],"Intradialytic Hypotension","End-Stage Renal Disease Requiring Haemodialysis",[188,189,190,191,63,192,193,194,195],"Carotid ultrasonography","Corrected flow time","Peak flow velocity variability","Intradialytic hypotension","Ultrasonographic predictors","Vascular ultrasonography","Fluid management","Dialysis safety","2025-06-14",{"date":198,"type":38},"2025-06-24",{"date":200,"type":38},"2025-02-01",{"date":202,"type":22},"2025-08-30",{"name":204,"class":45},"First Affiliated Hospital of Wannan Medical College",{"id":206,"slug":207,"hasResults":11,"nctId":208,"briefTitle":209,"officialTitle":210,"acronym":4,"eligibilityCriteria":211,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":212,"targetDuration":4,"studyType":23,"phases":214,"briefSummary":215,"conditions":216,"keywords":4,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":217,"lastUpdatePostDateStruct":218,"startDateStruct":220,"completionDateStruct":222,"leadSponsor":224,"locationsCount":81},"100535249","the-effect-of-lipus-on-the-maturation-of-newly-constructed-autogenous-avf-100535249","NCT06249373","The Effect of LIPUS on the Maturation of Newly Constructed Autogenous AVF","A Multicenter Randomized Controlled Trial on the Effect of Low-intensity Pulsed Ultrasound on the Maturation of Newly Constructed Autogenous Arteriovenous Fistulas in Uremic Patients","Inclusion Criteria:\n\n1.18 years old ≤ Age ≤ 75 years old, regardless of gender or ethnicity;\n\n2.Dialysis or non-dialysis patients who have newly established autologous arteriovenous fistula in the wrist and have not yet used the fistula for hemodialysis treatment;\n\n3.Before establishing an autologous arteriovenous fistula in the wrist, ultrasound examination will be performed. The radial artery diameter at the intended surgical site is\\>1.5mm, and the head vein diameter is\\>2mm （using a tourniquet）. The arterial and venous blood flow are unobstructed, and the distance between the vein and the skin is\\\u003C6mm;\n\n4\\. After introducing dialysis, the calcium ion concentration in the dialysate will be maintained at 1.5mmol\u002FL during the dialysis period, and low molecular weight heparin will be used for anticoagulation. The dosage of low molecular weight heparin remains unchanged （±1000U） during the study period;\n\n5\\. Sign an informed consent form.\n\nExclusion Criteria:\n\n1. Poor healing of internal fistula surgical incision;\n2. Active bacterial or viral infections;\n3. Pregnant women;\n4. The patient underwent kidney transplantation or was transferred to peritoneal dialysis during the study period;\n5. Subject ALT, AST ≥ 3 × upper limit of normal values;\n6. Within 3 months, according to NYHA classification, heart function is classified as level III-IV;\n7. Newly diagnosed unstable angina and cerebrovascular events within 3 months;\n8. Blood pressure below 90\u002F60mmHg or above 180\u002F100mmHg in the past 2 weeks;\n9. During the study period, patients did not follow medical advice and arbitrarily changed the types and dosages of other anticoagulants or anticoagulants (such as aspirin, clopidogrel, Agat Roban, etc.);\n10. Combine the use of glucocorticoids and immunosuppressants, such as tacrolimus, cyclosporine, MMF, azathioprine, leflunomide, Tripterygium wilfordii glycosides, etc;\n11. Other researchers consider inappropriate situations, such as coexisting with malignant tumors, where the expected lifespan is less than 6 months;\n12. I have participated in other clinical trials within 4 weeks prior to the start of this study.",{"count":213,"type":22},300,[93],"This study aims to evaluate the effect of 12 week low-intensity pulse ultrasound (LIPUS) intervention on the maturation of newly constructed autologous arteriovenous fistulas in uremic patients. This study is a prospective, blinded, randomized controlled trial. This trial is divided into two stages. The first stage is a concept validation trial, which is a single center, prospective, blinded, randomized controlled clinical study. Subjects who meet the screening criteria are randomly divided into an intervention group and a control group in a 1:1 ratio. All subjects underwent safety and efficacy evaluations at the 2nd, 4th, 8th, 12th, and 4th week after treatment. After completing a 4-week follow-up of the 20th study subject, an analysis was conducted with the preset goal of achieving a higher maturation rate of arteriovenous fistula in the intervention group compared to the control group at the follow-up point, and the safety of the study was evaluated. The second stage is a key trial, which is a multicenter, prospective, blinded, randomized controlled clinical study. The inclusion criteria, primary and secondary endpoints, and safety endpoints of the study subjects remain unchanged, and the safety and efficacy of the overall population are evaluated.",[31],"2024-05-13",{"date":219,"type":38},"2024-05-16",{"date":221,"type":38},"2024-02-26",{"date":223,"type":22},"2026-12-31",{"name":225,"class":45},"Suzhou Municipal Hospital"]